Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday. Celgene Corporation (NASDAQ: CELG) Maintained Buy with target of $73.00 at Cantor…
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around…
The 10-year Treasury hit yet another record low under 1.6% today and stocks are in the tank again due to poor economic data. Europe continues to face a meltdown and the hope…
A stock market that sells off eight of nine days is not a good market. Even the Facebook IPO is being viewed as a one-off item rather than a systemic item which…
Blame whatever you want. A weaker U.S. economy, a weakening and flailing Europe, a move to socialism in France and Greece, a weaker BRIC and emerging market story, commodity prices and on…
Markets opened higher this morning following a lower-than-expected GDP growth estimate of 2.2%. That was weaker, but not awful (our coverage here). The consumer sentiment survey rose a couple of ticks in…
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the biggest public merger rumors out there. At least that is the belief of Wall…
How many DJIA components can raise their dividend in one week? Johnson & Johnson (NYSE: JNJ) answered that question as “Who knows, but we can make it one more!” J&J has joined…
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company. With another small-cap to mid-cap biotech and emerging pharma company…
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from Bristol-Meyers…
Concerns about Spain and Italy renew capital markets’ rejection of area debt. (Reuters) Best Buy (NYSE: BBY) will have to bring in an outsider to change the company’s old philosophy. (Reuters) The…
Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug being reviewed…
Paul Ausick Drug maker Merck & Co. Inc. (NYSE: MRK) this morning lowered its first quarter non-GAAP EPS estimate to $0.95-$0.98, well below the previous consensus estimate of $1.03. For the full-year, Merck expects…
Paul Ausick Drug maker Merck & Co. Inc. (NYSE: MRK) has released results of a phase III study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen this morning. According to the company’s…
Paul Ausick The FDA announced today that the use of statins, common among people with high cholesterol, pose problems which were not mentioned on the lables on the drugs before. The agency reported that…
